全球瞩目的2025年欧洲肿瘤内科学会年会（ESMO Congress 2025）将于10月17日至21日在德国柏林盛大召开。
目前，ESMO官网已公布了全部摘要题目及讲者信息。【肿瘤资讯】特此整理了泌尿肿瘤领域入选LBA的重磅临床研究，带您一睹前沿风采。
主席全体大会 1
LBA2
Title：Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase 3 KEYNOTE-905 study
标题：围手术期维恩妥尤单抗联合帕博利珠单抗治疗不适合顺铂治疗的肌层浸润性膀胱癌患者：3期KEYNOTE-905研究
讲者：Christof Vulsteke (Gent, Belgium)
主席全体大会 2
LBA6
Title：Phase 3 trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
标题：[177Lu]Lu-PSMA-617联合ADT+ARPI治疗PSMA阳性转移性激素敏感性前列腺癌患者：3期PSMAddition临床试验
讲者：Scott T. Tagawa (New York, United States of America, US)
LBA7
Title：Disitamab vedotin (DV) plus toripalimab (T) versus chemotherapy (C) in first-line (1L) locally advanced or metastatic urothelial carcinoma (la/mUC) with HER2-expression
标题：维迪西妥单抗（DV）联合特瑞普利单抗（T）对比化疗（C）一线治疗HER2表达阳性局部晚期或转移性尿路上皮癌（la/mUC）
讲者：郭军 (北京, 中国)
主席全体大会 3
LBA8
Title：IMvigor011: a Phase 3 trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer
标题：IMvigor011研究：一项基于循环肿瘤DNA指导的阿替利珠单抗辅助治疗对比安慰剂用于肌层浸润性膀胱癌的3期临床试验
讲者：Thomas B. Powles (London, United Kingdom)
优选口头报告:
泌尿肿瘤, 前列腺癌 ，阴茎癌和睾丸癌
LBA86
Title：Randomised phase 3 trial of androgen deprivation therapy (ADT) with radiation therapy with or without enzalutamide for high risk, clinically localised prostate cancer: ENZARAD (ANZUP 1303)
标题：ENZARAD（ANZUP 1303）III期随机临床试验：雄激素剥夺治疗联合放疗±恩扎卢胺治疗高危临床局限性前列腺癌
讲者：Paul L. Nguyen (Boston, United States of America)
LBA88
Title：Final Results from PRESTO: A Phase 3 Open-label Study of Combined Androgen Blockade in Patients (pts) with High-risk Biochemically Relapsed Prostate Cancer (BRPC) (AFT-19)
标题：PRESTO研究最终结果：一项针对高危生化复发前列腺癌（BRPC）患者联合雄激素阻断治疗的III期开放标签研究（AFT-19）
讲者：Rahul Aggarwal (San Francisco, United States of America)
LBA87
Title：Overall survival with enzalutamide in biochemically recurrent prostate cancer
标题：恩扎卢胺在生化复发前列腺癌患者中的总生存期结果
讲者：Neal D. Shore (Myrtle Beach, United States of America)
迷你口头报告:
泌尿肿瘤, 前列腺癌 ，阴茎癌和睾丸癌
LBA91
Title：Patient (pt) reported outcomes (PROs) from AMPLITUDE, a randomized placebo-controlled phase 3 trial of niraparib (NIRA) and abiraterone acetate (AA) plus prednisone (P) in metastatic hormone-sensitive prostate cancer (mHSPC) with homologous recombination repair mutations (HRRm)
标题：AMPLITUDE研究患者报告结局：一项评估尼拉帕利联合醋酸阿比特龙及泼尼松对比安慰剂治疗携带同源重组修复突变的转移性激素敏感性前列腺癌的随机、安慰剂对照3期临床试验
讲者：Dana E. Rathkopf (New York, United States of America, NY)
LBA92
Title：3-Weekly Docetaxel 75 mg/m2 vs 2-Weekly Docetaxel 50 mg/m2 in Combination with Darolutamide + ADT in Patients with mHSPC – Results from the Randomised Phase 3 ARASAFE Trial
标题：ARASAFE III期随机临床试验结果：转移性激素敏感性前列腺癌患者中多西他赛（75 mg/m² 三周方案）对比多西他赛（50 mg/m² 两周方案）联合达罗他胺+ADT的疗效分析
讲者：Marc-Oliver Grimm (Jena, Germany)
LBA37
Title：A phase 2 study of Avelumab in Locally Advanced or Metastatic Penile Cancer Patients Unfit for Platinum-based chemotherapy or Progressed On or After Platinum-based Chemotherapy (ALPACA)
标题：一项评估阿维鲁单抗治疗不适合铂类化疗或铂类化疗后进展的局部晚期或转移性阴茎癌的2期研究（ALPACA）
讲者：Srikala S. Sridhar (Toronto, Canada)
优选口头报告: 放射配体疗法
LBA89
Title：A randomized phase 2 study of 177Lu-PSMA-617 vs docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC) and PSMA-positive disease: Canadian Cancer Trials Group (CCTG) study PR.21
标题：一项比较177Lu-PSMA-617与多西他赛治疗转移性去势抵抗性前列腺癌（mCRPC）伴PSMA阳性疾病的随机2期研究：加拿大癌症试验组（CCTG）PR.21研究
讲者：Kim Nguyen Chi (Vancouver, Canada, British Columbia)
LBA90
Title：Prospective Randomized Phase 2 trial of 177Lutetium-PSMA therapy Neoadjuvant to Stereotactic Ablative Radiotherapy for recurrent Oligo-Metastatic Hormone-Sensitive Prostate Cancer (LUNAR NCT05496959)
标题：针对复发性寡转移激素敏感性前列腺癌的前瞻性随机2期临床试验：177Lu-PSMA疗法新辅助治疗联合立体定向消融放疗（LUNAR NCT05496959）
讲者：Jeremie Calais (Los Angeles, United States of America)
优选口头报告1:
泌尿肿瘤, 肾癌 & 尿路上皮癌
LBA107
Title：ALBAN: A phase 3, randomized, open-label, international study of intravenous (iv) atezolizumab and intravesical Bacillus Calmette-Guérin (BCG) vs BCG alone in BCG-naïve high-risk, non-muscle-invasive bladder cancer (NMIBC)
标题：ALBAN研究：一项在BCG初治高风险非肌层浸润性膀胱癌（NMIBC）患者中比较静脉阿替利珠单抗联合膀胱内卡介苗与单用卡介苗的3期、随机、开放标签、国际性临床研究
讲者：Morgan Roupret (Paris, France)
LBA108
Title：Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): final analysis of the phase 3, open-label, randomised POTOMAC trial
标题：POTOMAC III期临床试验最终分析：度伐利尤单抗联合卡介苗治疗BCG初治高风险非肌层浸润性膀胱癌
讲者：Maria De Santis (Berlin, Germany)
LBA 109
Title：DISCUS: A phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.
标题：DISCUS II期研究：晚期尿路上皮癌中维持性阿维鲁单抗治疗前铂类化疗周期数比较（3周期 vs 6周期）
讲者：Enrique Grande Pulido (Madrid, Spain)
LBA110
Title：A blinded, exploratory phase 2 trial of nivolumab and the GDF-15 neutralizing antibody visugromab or placebo as neoadjuvant treatment of patients with muscle-invasive bladder cancer (MIBC): Primary results of the GDFather-NEO trial
标题：GDFather-NEO试验主要结果：纳武利尤单抗联合GDF-15中和抗体visugromab或安慰剂作为肌层浸润性膀胱癌（MIBC）新辅助治疗的盲法探索性II期研究
讲者：Andrea Necchi (Milan, Italy)
优选口头报告2:
泌尿肿瘤, 肾癌 & 尿路上皮癌
LBA96
Title：First-line Pembrolizumab-based Regimens for Advanced Clear Cell Renal Cell Carcinoma: KEYMAKER-U03 Substudy 03A
标题：基于帕博利珠单抗的一线方案治疗晚期透明细胞肾细胞癌：KEYMAKER-U03研究03A子研
讲者：Cristina Suarez Rodriguez (Barcelona, Spain)
LBA94
Title：LenCabo: A randomized phase II multicenter trial of lenvatinib plus everolimus (len/eve) versus (vs) cabozantinib (cabo) in patients (pts) with metastatic clear cell RCC (ccRCC) that progressed on PD-1 immune checkpoint inhibition (ICI)
标题：LenCabo II期随机多中心试验：仑伐替尼联合依维莫司（len/eve）对比卡博替尼（cabo）治疗PD-1免疫检查点抑制剂治疗后进展的转移性透明细胞肾细胞癌（ccRCC）患者
讲者：Andrew W. Hahn (Houston, United States of America)
LBA93
Title：First results from RAMPART: An international phase 3 randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL
标题：RAMPART试验首次结果：一项由伦敦大学学院MRC临床试验部门主导的国际III期随机对照试验——度伐利尤单抗单药或联合曲美木单抗辅助治疗用于切除后的原发性肾细胞癌
讲者：James Larkin (London, United Kingdom)
LBA95
Title：Neoadjuvant immunotherapy in locally advanced clear cell renal cell carcinoma at risk for recurrence or distant metastases: the randomized phase II NESCIO trial
标题：NESCIO II期随机试验：新辅助免疫治疗用于复发或远处转移风险的局部晚期透明细胞肾细胞癌
讲者：Femke Burgers (Amsterdam, Netherlands)
迷你口头报告1:
泌尿肿瘤, 肾癌 & 尿路上皮癌
LBA111
Title：Randomized Comparison of upfront Magnetic Resonance Imaging Versus Transurethral Resection for Staging New Bladder Cancers: Final survival analysis from the BladderPath trial
标题：膀胱癌初诊分期中磁共振成像与经尿道切除术的随机对照比较：BladderPath试验的最终生存分析
讲者：Nicholas D. James (London, United Kingdom)
LBA112
Title：Neoadjuvant gemcitabine intravesical system (TAR-200) + cetrelimab (CET) or CET alone in patients (pts) with muscle-invasive bladder cancer (MIBC): SunRISe-4 (SR-4) primary analysis and biomarker results
标题：SunRISe-4研究主要分析及生物标志物结果：新辅助TAR-200吉西他滨膀胱内给药系统联合 cetrelimab或 cetrelimab单药治疗肌层侵袭性膀胱癌
讲者：Andrea Necchi (Milan, Italy）
2025 ESMO官网
如有错漏，敬请留言补充！
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
